ArticleFrontiers in pharmacology2026

Low-dose dasatinib in second-line therapy or beyond for the treatment of chronic-phase chronic myeloid leukemia: a real-world cohort study.

Yilin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.